Selva Therapeutics, Inc., a San Diego, CA-based biotechnology company, raised $3m in Series A financing.
The company intends to use the funds to advance SLV213 into clinical trials as an oral drug candidate for the treatment of COVID-19, the disease caused by SARS-CoV-2 infection.
Led by Ted Daley, President and CEO, Selva Therapeutics is a biotechnology company dedicated to the development of therapeutics for infectious diseases. The company’s lead drug candidate, SLV213, is an orally available small molecule novel antiviral therapy with activity against a broad range of viruses that threaten global health, including SARS-CoV-2, the virus causing COVID-19.
In addition, SLV213 has activity against Ebola and Nipah viruses and has completed preclinical development as a potential therapy against Chagas disease, a parasitic disease endemic to South and Central America and spreading into the southern United States.
It was developed based on research from UC San Diego and is exclusively licensed to Selva Therapeutics.
FinSMEs
21/07/2020